TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

Area of Science:

• Immunotherapy
• Molecular Engineering
• Computational Biology

Background:

• Cancer pathogenesis involves multiple redundant and distinct mechanisms.
• Targeting multiple cancer markers simultaneously may improve therapeutic efficacy.
• Chimeric antigen receptors (CARs) are promising cancer therapies.

Purpose of the Study:

• To design and validate a novel bispecific CAR, TanCAR, for enhanced T cell-mediated cancer therapy.
• To investigate the feasibility of integrating computational tools for CAR design.
• To assess TanCAR's efficacy in targeting multiple tumor antigens and overcoming antigen escape.

Main Methods:

• Creation of a functional bispecific chimeric antigen receptor (TanCAR).
• Utilized computational tools, including structure and docking simulations, to design and predict TanCAR functionality.
• Tested TanCAR's ability to induce T cell reactivity against two tumor antigens in vitro and in an animal model.

Main Results:

• TanCAR demonstrated distinct T cell reactivity against two tumor antigens.
• Synergistic enhancement of T cell effector functions was observed when both antigens were targeted.
• TanCAR maintained T cell cytolytic ability despite the loss of one target antigen and controlled established tumors in vivo.

Conclusions:

• TanCAR is a feasible and effective bispecific molecule for T cell-mediated cancer therapy.
• This approach enhances specificity, overcomes antigen escape, and allows targeting of tumors and their microenvironment.
• Computational integration aids in the design and prediction of complex bispecific molecules for immunotherapy.